Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand

Autor: Maarten J. Postma, Suchada Jiamsiri, Arthorn Riewpaiboon, Naiyana Praditsitthikorn, Onwipa Rochanathimoke, Piyanit Tharmaphornpilas, Montarat Thavorncharoensap
Přispěvatelé: Value, Affordability and Sustainability (VALUE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Microbes in Health and Disease (MHD), Groningen Research Institute of Pharmacy
Rok vydání: 2021
Předmět:
Cost effectiveness
Cost-Benefit Analysis
national immunization program
Pilot Projects
Economic
medicine.disease_cause
Rotavirus Infections
Cohort Studies
COST-EFFECTIVENESS
03 medical and health sciences
0302 clinical medicine
Cost of Illness
VACCINES
Rotavirus
Environmental health
medicine
Humans
Pharmacology (medical)
LATIN-AMERICAN
030212 general & internal medicine
health care economics and organizations
Disease burden
Immunization Programs
GASTROENTERITIS
business.industry
030503 health policy & services
Health Policy
Infant
Newborn
Rotavirus Vaccines
Infant
RIX4414
General Medicine
vaccination
Thailand
EFFICACY
DIARRHEA
Rotavirus vaccine
Markov Chains
Vaccination
rotavirus
Immunization
Child
Preschool
SAFETY
Economic evaluation
Quality-Adjusted Life Years
0305 other medical science
business
Cohort study
Zdroj: Expert review of pharmacoeconomics & outcomes research, 21(4), 811-819. Taylor & Francis Group
ISSN: 1744-8379
1473-7167
DOI: 10.1080/14737167.2021.1932468
Popis: IntroductionWorld Health Organization recommends rotavirus vaccine for all national immunization programs (NIPs). To provide country-specific evidence, we conducted economic evaluation of a monovalent rotavirus vaccination using specific data of the pilot phase in Thailand.MethodA Markov model was adopted to compare the 2020 birth cohort once receiving rotavirus vaccination versus no vaccination from healthcare and societal perspective over five years. Data on disease burden, vaccine effectiveness, costs, and utilities were taken from a cohort study in two provinces of Thailand. Sensitivity analyses were performed to test the robustness of the results.ResultsRotavirus vaccination would reduce rotavirus diarrhea and costs of illness by 48% and 71%, respectively, over the first five years of life. At USD 13 per dose, vaccine was cost-effective with the ICERs of USD 4,114 and USD 1,571per QALY gained from healthcare and societal perspective, respectively. Results were sensitive to incidence and vaccine cost. The budget for vaccine purchasing was estimated at USD13 million per year.ConclusionIncorporating rotavirus vaccination into the NIP substantially reduced health and cost outcomes and was cost-effective for both perspectives. However, the government needs to negotiate vaccine price prior to program implementation to achieve favorable budget impact.
Databáze: OpenAIRE
Externí odkaz: